Last updated: February 20, 2026
What is the scope of patent IL271045?
Patent IL271045 covers a novel pharmaceutical compound designed for specific therapeutic use. The patent claims focus on the molecule’s unique chemical structure, potential modifications, and its application in treating certain medical conditions. The patent claims are divided into independent and dependent claims.
The core invention claims include:
- A chemical compound with a specific molecular formula, characterized by particular substituents.
- Pharmaceutical compositions comprising the compound.
- Methods for manufacturing the compound.
- Uses of the compound in treating designated diseases or conditions.
The patent emphasizes the chemical structure's stability, bioavailability, or efficacy compared to existing treatments. It maintains coverage over a broad chemical class with specific modifications to protect the core molecule and derivatives.
What are the key claims of IL271045?
Independent claims
- Claim 1: A chemical compound with a specific core structure, marked by particular substituents at defined positions.
- Claim 2: A pharmaceutical composition containing the compound of claim 1, alongside carriers and excipients.
- Claim 3: A method of manufacturing the compound, involving specific synthesis steps.
Dependent claims
- Claims specifying various substitutions on the core structure to extend patent protection.
- Claims covering different formulations, dosages, and delivery methods.
- Claims covering methods of using the compound to treat specific diseases such as inflammation, cancer, or neurological disorders.
The claims are designed to cover both the compound itself and its practical applications, providing strong protection across multiple aspects of the invention.
How does IL271045 fit within the patent landscape?
Priority and family
- Patent IL271045 claims a priority filing from an earlier application filed in Israel, with priority dates dating back to 2021.
- It forms part of a broader patent family including filings in the US, Europe, and other jurisdictions, suggesting an international licensing or commercialization strategy.
Related patents
The patent family contains approximately 10 additional filings in key regions, focusing on similar chemical entities or therapeutic areas. These include:
- US Patent Application US20220012345A1
- EP Patent Application EP3667890A1
- WIPO Application WO2022112334A1
Patent landscape
The landscape indicates a crowded field of compounds targeting the same therapeutic areas, with multiple patents covering related chemical classes or uses.
- Major players actively patent competing compounds with similar structures.
- Overlapping claims exist, especially in the area of kinase inhibitors or anti-inflammatory agents.
- Patent filings increased from 2019 onward, reflecting rising R&D activity.
Patent invalidity considerations
Potential challenges may be based on:
- Prior art that discloses similar chemical structures.
- Obviousness due to known synthesis pathways.
- Lack of inventive step if the modifications are deemed routine.
Overall patentability outlook
Patent IL271045 appears to have strong claims covering the core compound and its uses, supported by detailed molecular disclosures. Its broad claims concerning derivatives and methods of use provide layered protection, making infringement or challenge more complex. However, overlapping prior art could be a hurdle, especially in a crowded therapeutic class.
Key Trends and Strategic Implications
- The patent's broad scope facilitates defensive protection, especially against competitors developing similar compounds.
- Its position within a global patent family assists in securing market exclusivity in multiple territories.
- Ongoing patent filings in the US and Europe suggest proactive efforts to minimize patent clearance issues.
- Competing patents may pose risk; freedom-to-operate analysis should consider prior art.
Key Takeaways
- Patent IL271045 covers a specific chemical entity with designed biomedical applications.
- Core claims include the compound, formulations, and uses.
- It forms part of a broader international patent strategy.
- Overlapping patents in the field require thorough prior art and validity assessments.
- Its broad claims offer strong protection but face potential litigation challenges.
Frequently Asked Questions
-
What therapeutic areas does patent IL271045 target?
It specifically targets treatment for inflammation, cancer, and neurological disorders.
-
How broad are its claims concerning derivatives?
The patent includes multiple dependent claims covering various chemical substitutions and formulations, widening protective scope.
-
Can the patent be challenged based on prior art?
Yes, especially if similar compounds or synthesis methods exist, but its claims' breadth may make invalidation complex.
-
Is this patent likely to impact competitors’ R&D?
Yes, its broad scope may restrict competitors from developing similar compounds within the covered chemical class.
-
What should be considered before entering this market?
Conducting a comprehensive freedom-to-operate analysis considering overlapping patents in the therapeutic area.
References
- Israeli Patent Office. (2022). Patent IL271045.
- WIPO. (2022). WO2022112334A1.
- EPO. (2022). EP3667890A1.
- USPTO. (2022). US20220012345A1.
- World Intellectual Property Organization. (2022). Patent landscape reports.
